Growth hormone therapy in Ullrich-Turner syndrome. Expert workshop consensus

Therapy with recombinant human growth hormone (GH) of short-statured girls with Ull rich Turner syndrome (UTS) has been authorized in Germany since 1991. To date, the daily recommended GH dose has been 50 mu g/kg, (s c. injection). By comparing different GH doses, it could be shown in recent years that height gain was much better in those girls who were treated with a higher GH dose than girls treated with the recommended dose Therefore, upon request of the company Novo Nordisk, the European Medicines Agency (EMEA) recently authorized a GH dose of 46-67 mu g/kg/day for the treatment of this patient population The current report summarizes the results of an expert workshop of pediatric endocrinologists, which was held to review the present position of GH therapy in girls with Turner syndrome in light of the higher GH dose. The workshop addressed issues such as the current status of therapy, the background to the dose increase, whether the dose should be increased in general or only in certain cases, possible risks, dosage adjustments, approaches in puberty, as well as ending therapy and transition to adult medicine.